[CH3:1][S:2][C:3]1[N:12]=[CH:11][C:10]2[CH:9]=[CH:8][C:7]3[C:13]([C:16]([O:18][CH2:19][CH3:20])=[O:17])=[N:14][NH:15][C:6]=3[C:5]=2[N:4]=1.C(=O)([O-])[O-].[Cs+].[Cs+].Br[CH2:28][CH2:29][N:30]([CH3:32])[CH3:31].O>CN(C)C=O>[CH3:31][N:30]([CH3:32])[CH2:29][CH2:28][N:15]1[C:6]2[C:5]3[N:4]=[C:3]([S:2][CH3:1])[N:12]=[CH:11][C:10]=3[CH:9]=[CH:8][C:7]=2[C:13]([C:16]([O:18][CH2:19][CH3:20])=[O:17])=[N:14]1To a solution of ethyl 8-(methylsulfanyl)-1H-pyrazolo[4,3-h]quinazoline-3-carboxylate (150 mg, 0.52 mmol) in dry dimethylformamide (4 ml) was added cesium carbonate (339 mg 1.04 mmol) followed by 2-bromo-N,N-dimethylethanamine (135 mg 0.88 mmol). The heterogeneous mixture was stirred at room temperature for 24 hours. The mixture was treated with water and extracted with EtOAc. The organic layer washed with brine, dried over Na2SO4 and concentrated. The crude was purified by silica gel chromatography eluting with EtOAc/Ethanol 85/15 to give ethyl 1-[2-(dimethylamino)ethyl]-8-(methylsulfanyl)-1H-pyrazolo[4,3-h]quinazoline-3-carboxylate as the major isomer (60 mg 32%) 1H NMR (401 MHz, DMSO-d6) δ 9.51 (s, 1H), 8.16 (d, J=8.67 Hz, 1H), 7.83 (d, J=8.79 Hz, 1H), 5.29 (t, J=6.59 Hz, 1H), 4.32-4.49 (m, 2H), 2.94 (br. s., 2H), 2.71 (s, 3H), 2.24 (br. s., 6H), 1.41 (t, J=7.08 Hz, 3H); and